– UK, London – AstraZeneca PLC (LON: AZN | STO: AZN | Nasdaq: AZN) today announced the appointment of Dr. Aradhana Sarin to its Board as an Executive Director and CFO, conditional upon closing of the acquisition of Alexion Pharmaceuticals, Inc. and effective on the later of 1 August 2021 or the date of Closing.
Dr. Sarin is currently EVP, CFO of Alexion, and will relocate from the US and be based in the UK. She will report to CEO, Pascal Soriot.
Dr. Sarin will succeed Marc Dunoyer who will step down as CFO and retire from the Board.
Conditional upon Closing and effective the same date as his retirement from AstraZeneca’s Board, Mr. Dunoyer will become CEO, Alexion, and Chief Strategy Officer, AstraZeneca. He will continue to report to Mr. Soriot and remain a Senior Executive Team member of AstraZeneca.
Leif Johansson, Chairman of AstraZeneca said “On behalf of the Board, I’d like to thank Marc for his significant contribution to AstraZeneca’s success since he joined us in 2013. We’re pleased he’s staying with the Company, taking on a new senior executive role, and looking forward to working with him.
“In Aradhana Sarin, we’ve appointed a talented successor to Marc as an Executive Director and CFO. The Board warmly welcomes her to AstraZeneca.”
Pascal Soriot, CEO said “I’d like to pay tribute to Marc for his tremendous achievements since he joined our company, and thank him personally for his outstanding support these past years. I’m looking forward to working with him in his new role as CEO, Alexion, the Rare Disease Unit of AstraZeneca, and to his continued strategic input to AstraZeneca’s success. I’m delighted Aradhana has agreed to become AstraZeneca’s next CFO and I look forward to working with her as the Company embarks on the next stage of its journey.”
About Aradhana Sarin
Dr. Aradhana Sarin is currently CFO at Alexion. She joined Alexion in November 2017, serving as Chief Business and Strategy Officer before becoming CFO. She has more than 20 years of professional experience spanning operating roles at Alexion and advisory roles at global financial institutions, gaining extensive knowledge of global healthcare systems, capital markets, and strategic transactions.
Before joining Alexion, Dr. Sarin was Managing Director, Healthcare Corporate & Investment Banking, Citi Global Banking in New York where she advised clients in the life sciences and biopharmaceutical sectors. Before that, she was Managing Director, Healthcare Investment Banking, UBS, in New York and San Francisco, and worked at JP Morgan in New York in the M&A Advisory and Healthcare groups.
Before her banking career, Dr. Sarin trained as a medical doctor in India and spent two years practicing in both India and Africa. She completed her medical training (M.B.B.S.) at the University of Delhi in India and received her MBA from Stanford Business School in the US.
From 2018 to 2020, Dr. Sarin was a member of the board of OraSure Technologies, Inc., serving as Chairman of the Audit Committee and a member of the Nominating and Corporate Governance Committee.
AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
For more information : https://www.astrazeneca.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.